Clinical Trial Details

USOR 17082

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Breast Cancer
Study Type: Non-Interventional
Phase: III
Study Start Date: 06/01/2018
Study Completion Date: 06/2027

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

 

NCT Number

NCT03155997

Principal Investigator(s)

John Wallmark, MD

Sponsor(s)

Eli Lilly and Company

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female